Cited by 1,930Erythropoietin and Anemia TreatmentDialysis and Renal Disease ManagementBlood transfusion and management

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Open access

Besarab, Anatole, Bolton, W. Kline, Browne, Jeffrey K., Egrie, Joan C., Nissenson, Allen R., Okamoto, Douglas M., Schwab, Steve J., Goodkin, David A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199808273390903

Open this paper in CoChat — free account Open PDF

Abstract

BackgroundIn patients with end-stage renal dis- ease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially.We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis. MethodsWe studied 1233 patients with clinical ev- idence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study.The median duration of treatment was 14 months.The primary end point was the length of time to death or a first nonfatal myocardial infarction. ResultsAfter 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the lowhematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9).Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted.The causes of death in the two groups were similar.The mortality rates decreased with increasing hematocrit values in both groups.The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group. ConclusionsIn patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.(N

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199808273390903

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men
Salonen, J. T., Nyyssönen, K., Korpela, H., Tuomilehto, J., Seppänen, R., & Salonen, R. (1992) · Circulation · doi:10.1161/01.cir.86.3.803 · Cited by 1,284
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citation
Impact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barré, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 780
Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
(1990) · BMJ · doi:10.1136/bmj.300.6724.573 · Cited by 427
The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin
Evans, R. W. (1990) · JAMA · doi:10.1001/jama.263.6.825 · Cited by 401

Show all 28 references

Research works printed but not linked: 8

Pascual J, 1991, Clin Nephrol, 35, 280
Eschbach JW, 1993, J Am Soc Nephrol, 4, 425
Collins A, 1994, J Am Soc Nephrol, 5, 439
Nissenson AR, 1996, J Am Soc Nephrol, 7, 1459
Barany P, 1996, J Am Soc Nephrol, 7, 1472
Benz RL, 1996, J Am Soc Nephrol, 7, 1473
Hoen B, 1995, Nephrol Dial Transplant, 10, 377
Collins A, 1997, J Am Soc Nephrol, 8, 190A

Sorted by citations

Items 601–700 of 1,000

ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?
Vecchio, L. D., & Minutolo, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040839 · Cited by 28
ANAEMIA, DIABETES AND CHRONIC KIDNEY DISEASE: WHERE ARE WE NOW?
Stevens, P. E. (2012) · Journal of Renal Care · doi:10.1111/j.1755-6686.2012.00281.x · Cited by 28
Diabetes, kidney disease and anaemia: time to tackle a troublesome triad?
Al-Khoury, S., Afzali, B., Shah, N., Thomas, S., Gusbeth–Tatomir, P., Goldsmith, D. J. A., & Covic, A. C. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01259.x · Cited by 28
Editorials: Recombinant Human Erythropoietin: Has Treatment Reached its Full Potential?
Fishbane, S. N. (2006) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2006.00109.x · Cited by 28
Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes
Ibrahim, H. N., Skeans, M. A., Li, Q., Ishani, A., & Snyder, J. J. (2011) · Clinical Transplantation · doi:10.1111/j.1399-0012.2011.01397.x · Cited by 27
2009
Goldsmith, D. J. A. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09131209 · Cited by 27
Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy
Jhund, P. S., Petrie, M. C., Robertson, M., Mark, P. B., MacDonald, M. R., Connolly, E. C., Anker, S. D., Bhandari, S., Farrington, K., Kalra, P. A., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.04.005 · Cited by 27
Physical Activity and Exercise for Cardiorespiratory Health and Fitness in Chronic Kidney Disease
Gollie, J. M., Cohen, S. D., & Patel, S. S. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2308273 · Cited by 27
Erythropoietic Response After Intravenous Iron in Patients with Heart Failure and Reduced Ejection Fraction with and Without Background Treatment with Sodium–Glucose Cotransporter 2 Inhibitors
Marques, P. S., Matias, P., Packer, M., Vieira, J. T., Vasques‐Nóvoa, F., Sharma, A., Mavrakanas, T. A., Friões, F., & Ferreira, J. P. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2992 · Cited by 27
Effect of Roxadustat on Thyroid Function in Patients With Renal Anemia
Haraguchi, T., Hamamoto, Y., Kuwata, H., Yamazaki, Y., Nakatani, S., Hyo, T., Yamada, Y., Yabe, D., & Seino, Y. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad483 · Cited by 27
Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013
Evans, M., Suttorp, M., Bellocco, R., Hoekstra, T., Qureshi, A. R., Dekker, F. W., & Carrero, J. J. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv298 · Cited by 27
Management of the Dialysis Patient with Sickle Cell Disease
Boyle, S. M., Jacobs, B., Sayani, F. A., & Hoffman, B. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12403 · Cited by 27
Biomedical System Dynamics to Improve Anemia Control With Darbepoetin Alfa in Long-Term Hemodialysis Patients
McCarthy, J. T., Hocum, C. L., Albright, R. C., Rogers, J. R., Gallaher, E. J., Steensma, D. P., Gudgell, S. F., Bergstralh, E. J., Dillon, J. C., Hickson, L. J., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.10.022 · Cited by 27
Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009
Regidor, D. L., McClellan, W. M., Kewalramani, R., Sharma, A. K., & Bradbury, B. D. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq573 · Cited by 27
Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials
Ye, Y., Liu, H., Chen, Y., Zhang, Y., Li, S., Hu, W., Yang, R., Zhang, Z., Lv, L., & Liu, X. (2018) · Renal Failure · doi:10.1080/0886022x.2018.1532909 · Cited by 27
Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels
Roberts, T. L., Foley, R. N., Weinhandl, E. D., Gilbertson, D. T., & Collins, A. J. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfk095 · Cited by 27
Perioperative Anämie
Kulier, A., & Gombotz, H. (2001) · Der Anaesthesist · doi:10.1007/s001010050968 · Cited by 27
Warning Flags for Erythropoiesis-Stimulating Agents and Cancer-Associated Anemia
Lappin, T. R. J., Maxwell, A. P., & Johnston, P. G. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-362 · Cited by 27
After 15 years of success—perspectives of erythropoietin therapy
Eckardt, K. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.9.1745 · Cited by 27
Editorial: The Optimal Hemoglobin in Dialysis Patients— A Critical Review
Singh, A. K., & Fishbane, S. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00329.x · Cited by 27
Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS)
Andreotti, F., Agati, L., Conti, E., Santucci, E., Rio, T., Tarantino, F., Natale, L., Berardi, D., Mattatelli, A., Musumeci, B., et al. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0363-x · Cited by 26
The Effect of High-Flux Hemodialysis on Hemoglobin Concentrations in Patients with CKD
Schneider, A., Drechsler, C., Krane, V., Krieter, D. H., Scharnagl, H., Schneider, M. P., & Wanner, C. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02710311 · Cited by 26
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease
Kurata, Y., Tanaka, T., & Nangaku, M. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000617 · Cited by 26
Anaemia management in patients with chronic kidney disease: T aiwan practice guidelines
Hung, S., Kuo, K., Tarng, D., Hsu, C., Wu, K., & Huang, T. (2014) · Nephrology · doi:10.1111/nep.12332 · Cited by 26
Erythropoietin and Resistant Hypertension in CKD
Boyle, S. M., & Berns, J. S. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.08.008 · Cited by 26
Iron deficiency anemia in heart failure
Arora, N. P., & Ghali, J. K. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9342-y · Cited by 26
Effect of Medicare Dialysis Payment Reform on Use of Erythropoiesis Stimulating Agents
Swaminathan, S., Mor, V., Mehrotra, R., & Trivedi, A. N. (2014) · Health Services Research · doi:10.1111/1475-6773.12252 · Cited by 26
The effect of epoetin dose on hematocrit
Cotter, D., Zhang, Y., Thamer, M., Kaufman, J. S., & Hernán, M. Á. (2007) · Kidney International · doi:10.1038/sj.ki.5002688 · Cited by 26
Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease
Rodríguez‐Iturbe, B., & Correa‐Rotter, R. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003796570 · Cited by 26
Hemoglobin Variability with Epoetin Beta and Continuous Erythropoietin Receptor Activator in Patients on Peritoneal Dialysis
Selby, N. M., Fonseca, S., Fluck, R., & Taal, M. W. (2011) · Peritoneal Dialysis International · doi:10.3747/pdi.2010.00299 · Cited by 26
Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation
Pai, A. B. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13461 · Cited by 26
Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Akizawa, T., Tanaka‐Amino, K., Otsuka, T., & Yamaguchi, Y. (2021) · American Journal of Nephrology · doi:10.1159/000519043 · Cited by 26
Risk of Vascular access Thrombosis in Patients with Systemic Lupus Erythematosus on Hemodialysis
Shafi, S., & Gupta, M. (2007) · The Journal of Vascular Access · doi:10.1177/112972980700800207 · Cited by 26
Bench to bedside: A role for erythropoietin in sepsis
Walden, A. P., Young, D., & Sharples, E. J. (2010) · Critical Care · doi:10.1186/cc9049 · Cited by 26
Factor analysis of various anaerobic power tests.
Manning, J. M., DOOLY-MANNING, C. R., & Perrin, D. H. (1988) · PubMed · Cited by 26
Strategies to decrease cardiovascular mortality in patients with end-stage renal disease
Dikow, R., Adamczak, M., Henriquez, D. E., & Ritz, E. (2002) · Kidney International · doi:10.1046/j.1523-1755.61.s80.3.x · Cited by 26
Design of the Blood Pressure Goals in Dialysis Pilot Study
Gul, A., Harford, A., Horowitz, B., Bedrick, E. J., Miskulin, D. C., Gassman, J., Chen, J. L. T., Paine, S., Kusek, J. W., Unruh, M. L., et al. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31827daee5 · Cited by 25
Determining Optimum Hemoglobin Sampling for Anemia Management from Every-Treatment Data
Gawęda, A. E., Nathanson, B. H., Jacobs, A. A., Aronoff, G. R., Germain, M. J., & Brier, M. E. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03540410 · Cited by 25
Eisenmangel, Thrombozytose und Thromboembolie
Evstatiev, R. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0514-6 · Cited by 25
Anemia
Santis, G. C. D. (2019) · Medicina (Ribeirão Preto) · doi:10.11606/issn.2176-7262.v52i3p239-251 · Cited by 25
Thrombectomy approach for access maintenance in the end stage renal disease population: a narrative review
Wu, V., Kalva, S. P., & Cui, J. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-21-523 · Cited by 25
Health‐related quality of life in the era of erythropoietin
Weisbord, S. D., & Kimmel, P. L. (2008) · Hemodialysis International · doi:10.1111/j.1542-4758.2008.00233.x · Cited by 25
Current Perspectives on Protective Roles of Erythropoietin in Cardiovascular System: Erythropoietin Receptor as a Novel Therapeutic Target
Kagaya, Y., Asaumi, Y., Wang, W. “., Takeda, M., Nakano, M., Satoh, K., Fukumoto, Y., & Shimokawa, H. (2012) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.227.83 · Cited by 25
Greater Epoetin alfa (EPO) doses and short‐term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL
Bradbury, B. D., Do, T. P., Winkelmayer, W. C., Critchlow, C. W., & Brookhart, M. A. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1799 · Cited by 25
Hemoglobin concentration and the risk of hemorrhagic and ischemic stroke in patients undergoing hemodialysis: the Q-cohort study
Yotsueda, R., Tanaka, S., Taniguchi, M., Fujisaki, K., Torisu, K., Masutani, K., Hirakata, H., Kitazono, T., & Tsuruya, K. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx305 · Cited by 25
Obesity may be erythropoietin dose-saving in hemodialysis patients
El-Kannishy, G. M., Megahed, A. F., Tawfik, M., El‐Said, G., Zakaria, R. T., Mohamed, N. A., Taha, E. M., Ammar, A. A., Eltawab, A. M. A., & Sayed‐Ahmed, N. (2018) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.2018.37.2.148 · Cited by 25
Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period
Karaboyas, A., Morgenstern, H., Waechter, S., Fleischer, N. L., Vanholder, R. C., Jacobson, S. H., Sood, M. M., Schaubel, D. E., Inaba, M., Pisoni, R. L., et al. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz065 · Cited by 25
Red Blood Cell Dysfunction in Critical Illness
Rogers, S. C., & Doctor, A. (2020) · Critical Care Clinics · doi:10.1016/j.ccc.2019.12.008 · Cited by 25
Patient Blood Management
Gombotz, H., & Hofmann, A. (2013) · Der Anaesthesist · doi:10.1007/s00101-013-2199-1 · Cited by 25
Intravenous iron therapy in renal failure: Friend and foe?
Afzali, B., & Goldsmith, D. J. A. (2004) · Journal of Nephrology · doi:10.1093/joneph/17.4.487 · Cited by 25
Renal dysfunction is a frequent complication in patients with advanced stage of Duchenne muscular dystrophy
Matsumura, T., Saito, T., Fujimura, H., & Sakoda, S. (2012) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.52.211 · Cited by 25
Darbepoetin‐α: A Review of the Literature
Overbay, D. K., & Manley, H. J. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.11.889.33633 · Cited by 25
2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA)
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 28
Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model
Suttorp, M., Hoekstra, T., Mittelman, M., Ott, I., Krediet, R. T., Dekker, F. W., & Putter, H. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3855 · Cited by 24
Clinical Factors and the Decision to Transfuse Chronic Dialysis Patients
Whitman, C. B., Shreay, S., Gitlin, M. D., van Oijen, M. G. H., & Spiegel, B. M. R. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00160113 · Cited by 24
Comparison of Bleeding Risk Scores in Elderly Patients Receiving Extended Anticoagulation with Vitamin K Antagonists for Venous Thromboembolism
Frei, A. N., Stalder, O., Limacher, A., Méan, M., Baumgartner, C., Rodondi, N., & Aujesky, D. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1726345 · Cited by 24
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease
Koury, M. J., Agarwal, R., Chertow, G. M., Eckardt, K., Fishbane, S. N., Ganz, T., Haase, V. H., Hanudel, M. R., Parfrey, P. S., Pérgola, P. E., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26644 · Cited by 25
Strategies and Outcomes of Cardiac Surgery in Jehovah's Witnesses
Moraca, R. J., Wanamaker, K. M., Bailey, S. H., McGregor, W. E., Benckart, D. H., Maher, T. D., & Magovern, G. J. (2011) · Journal of Cardiac Surgery · doi:10.1111/j.1540-8191.2011.01215.x · Cited by 24
Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period
Tran, D. H., Wong, G. T., Chee, Y. E., & Irwin, M. G. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.858116 · Cited by 24
Protecting the confidentiality of interim data: Addressing current challenges
Fleming, T. R. (2014) · Clinical Trials · doi:10.1177/1740774514561243 · Cited by 24
Interventions for erythropoietin-resistant anaemia in dialysis patients
Badve, S. V., Beller, E., Cass, A., Francis, D. P., Hawley, C. M., Macdougall, I. C., Perkovic, V., & Johnson, D. W. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006861.pub3 · Cited by 24
The Controversy Surrounding Hemoglobin and Erythropoiesis-Stimulating Agents: What Should We Do Now?
Singh, A. K. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.09.010 · Cited by 24
Preoperative Hemoglobin and Outcomes in Patients with CKD Undergoing Cardiac Surgery
Shavit, L., Hitti, S., Silberman, S., Tauber, R., Merin, O., Lifschitz, M. D., Slotki, I. N., Bitran, D., & Fink, D. L. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00110114 · Cited by 24
Effect of Hemodialysis on Whole Blood Viscosity
Vaisman, S., Kensey, K. R., & Cho, Y. I. (2009) · The International Journal of Artificial Organs · doi:10.1177/039139880903200603 · Cited by 24
The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: Rationale and study design of a randomized controlled pilot study
Walsh, M. W., Manns, B., Klarenbach, S. W., Quinn, R. R., Tonelli, M. A., & Culleton, B. F. (2006) · BMC Nephrology · doi:10.1186/1471-2369-7-2 · Cited by 24
Clinical and Economic Impact of Epoetins in Cancer Care
Marchetti, M., & Barosi, G. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422160-00001 · Cited by 24
Atherosclerosis in Dialyzed Patients
Ritz, E. (2004) · Blood Purification · doi:10.1159/000074921 · Cited by 24
Anemia of Chronic Disease
Besarab, A., & Hemmerich, S. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7360-6_4 · Cited by 24
Self-citation
Should Hemoglobin be Normalized in Patients with Chronic Kidney Disease?
Stevens, L., Stigant, C. E., & Levin, A. (2002) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2002.00004.x · Cited by 24
Thrombocytosis in EPO-Treated Dialysis Patients May Be Mediated by EPO Rather Than Iron Deficiency
Vaziri, N. D. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.030 · Cited by 23
Peripheral Vein Thrombophlebitis in the Upper Extremity: A Systematic Review of a Frequent and Important Problem
Heng, S. Y., Yap, R. T. J., Tie, J. L., & McGrouther, D. A. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.054 · Cited by 23
Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease
Minutolo, R., Garofalo, C., Chiodini, P., Aucella, F., Vecchio, L. D., Locatelli, F., Scaglione, F., & Nicola, L. D. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa088 · Cited by 23
Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure
Parfrey, P. S. (2010) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283428bc2 · Cited by 23
RBC Transfusions Among Hemodialysis Patients (1999-2010): Influence of Hemoglobin Concentrations Below 10 g/dL
Gilbertson, D. T., Monda, K. L., Bradbury, B. D., & Collins, A. J. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.05.004 · Cited by 23
Acute Kidney Injury in the Intensive Care Unit
Crowley, S. T., & Peixoto, A. J. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2008.09.002 · Cited by 23
Ischemic and Hemorrhagic Stroke: High Incidence in Hemodialysis and Peritoneal Dialysis Patients
Drew, D. A., & Sarnak, M. J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.01.009 · Cited by 23
Targeting optimal PD management in children: what have we learned from the IPPN registry?
Borzych–Dużałka, D., Schaefer, F. S., & Warady, B. A. (2020) · Pediatric Nephrology · doi:10.1007/s00467-020-04598-0 · Cited by 23
Cardio-renal anemia syndrome.
Efstratiadis, G., Konstantinou, D. M., Chytas, I., & Vergoulas, G. (2008) · PubMed Central · Cited by 23
What are the clinical consequences of anemia in patients with chronic heart failure?
McMurray, J. J. V. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2004.01.001 · Cited by 23
Pathogenesis of Cardiac Disease in Dialysis Patients
Parfrey, P. S. (1999) · Seminars in Dialysis · doi:10.1046/j.1525-139x.1999.00008.x · Cited by 23
An integrated approach to prognosis using protein microarrays and nonparametric methods
Knickerbocker, T., Chen, J. R., Thadhani, R., & MacBeath, G. (2007) · Molecular Systems Biology · doi:10.1038/msb4100167 · Cited by 23
Characteristics and Performance of Minority‐Serving Dialysis Facilities
Hall, Y. N., Xu, P., Chertow, G. M., & Himmelfarb, J. (2013) · Health Services Research · doi:10.1111/1475-6773.12144 · Cited by 22
Chronic Kidney Disease Mineral Bone Disorder and Health-Related Quality of Life Among Incident End-Stage Renal-Disease Patients
Johansen, K. L., & Chertow, G. M. (2007) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2007.06.005 · Cited by 22
International Society for Heart and Lung Transplantation Developed in Collaboration With the Force on Practice Guidelines: American College of Cardiology Foundation/American Heart Association Task Diagnosis and Management of Heart Failure in Adults: A Report of the 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the
Stevenson, W., Yancy, C. W., Mancini, M. E., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Francis, S. A., Ganiats, T. G., Jessup, M. L., et al. (2009) · Cited by 22
Effect of Facility-Level Hemoglobin Concentration on Dialysis Patient Risk of Transfusion
Collins, A. J., Monda, K. L., Molony, J. T., Li, S., Gilbertson, D. T., & Bradbury, B. D. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.052 · Cited by 22
Association Between Vascular Access Dysfunction and Subsequent Major Adverse Cardiovascular Events in Patients on Hemodialysis
Kuo, T.-H., Tseng, C.-T., Lin, W., Chao, J.-Y., Wang, W., Li, C., & Wang, M. (2015) · Medicine · doi:10.1097/md.0000000000001032 · Cited by 22
Safety Issues in Iron Treatment in CKD
Vaziri, N. D. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.02.005 · Cited by 23
Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia
Maruyama, T., Higuchi, T., Yamazaki, T., Okawa, E., Ando, H., Oikawa, O., Inoshita, A., Okada, K., & Abe, M. (2017) · Cardiorenal Medicine · doi:10.1159/000462983 · Cited by 22
Artesunate and erythropoietin synergistically improve the outcome of experimental cerebral malaria
Du, Y., Chen, G., Zhang, X., Yu, C., Cao, Y., & Cui, L. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.05.008 · Cited by 22
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease
Kurata, Y., Tanaka, T., & Nangaku, M. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1993821 · Cited by 22
Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysis
Irving, M. J., Craig, J. C., Gallagher, M., McDonald, S., Polkinghorne, K. R., Walker, R. G., & Roger, S. D. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00584.x · Cited by 22
Negative trials in nephrology: what can we learn?
Novak, J. E., Inrig, J. K., Patel, U. D., Califf, R. M., & Szczech, L. A. M. (2008) · Kidney International · doi:10.1038/ki.2008.286 · Cited by 22
Cardio-renal insufficiency: the search for management strategies
Gil, P., Justo, S., Castilla, M. Á., Criado, C., & Caramelo, C. A. (2005) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000170753.41279.70 · Cited by 22
Human pluripotent stem cell–derived erythropoietin-producing cells ameliorate renal anemia in mice
Hitomi, H., Kasahara, T., Katagiri, N., Hoshina, A., Mae, S.-I., Kotaka, M., Toyohara, T., Rahman, A., Nakano, D., Niwa, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2300 · Cited by 22
The Effects of Pre- and Post-transplant Anemia on 1-Year Survival After Cardiac Transplantation
Taegtmeyer, A. B., Rogers, P., Breen, J. B., Barton, P. J. R., Banner, N. R., & Yacoub, M. H. (2008) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.01.014 · Cited by 22
Treatment of anemia in patients with chronic heart failure
Katz, S. D., MANCINI, D. M., Androne, A. S., & Hryniewicz, K. M. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2004.01.002 · Cited by 22
Anemia in Chronic Kidney Disease and Congestive Heart Failure
Silverberg, D. S., Wexler, D., Blüm, B., & Iaina, A. (2003) · Blood Purification · doi:10.1159/000067856 · Cited by 22
Haemoglobin level and vascular access survival in haemodialysis patients
Garrancho, J. M., Kirchgessner, J., Arranz, M., Klinkner, G., Rentero, R., Ayala, J. A., & Marcelli, D. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi027 · Cited by 22
Editorial: Intersecting Guidelines: Administering Erythropoiesis‐Stimulating Agents to Chronic Kidney Disease Patients with Cancer
Bennett, C. L., Becker, P. S., Kraut, E. H., Samaras, A. T., & West, D. P. (2008) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2008.00524.x · Cited by 22
The Perioperative Surgical Home, Enhanced Recovery After Surgery and how integration of these models may improve care for medically complex patients
Harrison, T. G., Ronksley, P. E., James, M. T., Brindle, M. E., Ruzycki, S. M., Graham, M. M., McRae, A. D., Zarnke, K. B., McCaughey, D., Ball, C. G., et al. (2021) · Canadian Journal of Surgery · doi:10.1503/cjs.002020 · Cited by 21

Authors: Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A.
Affiliations: Henry Ford Hospital (US)
University of Virginia Health System (US)
Amgen (United States) (US)
University of California, Los Angeles (US)
Duke University (US)
ORCID: Bolton, W. Kline
Goodkin, David A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-08-27
Volume: 339
Issue: 9
Pages: 584-590
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199808273390903
OpenAlex: W2331665138
Cited by: 1,930
References: 28
Citations by year: 2026: 23 · 2025: 33 · 2024: 36 · 2023: 44 · 2022: 52 · 2021: 82 · 2020: 59 · 2019: 61 · 2018: 59 · 2017: 68 · 2016: 75 · 2015: 56 · 2014: 89 · 2013: 102 · 2012: 99
FWCI: 21.09
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
Health Sciences › Medicine › Hematology › Blood transfusion and management
Keywords: hematocrit, recombinant human erythropoietin, epoetin, hemodialysis, end-stage renal disease, anemia, congestive heart failure, ischemic heart disease, myocardial infarction, mortality, dialysis adequacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks